Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.

Weinberg BA, Xiu J, Lindberg MR, Shields AF, Hwang JJ, Poorman K, Salem ME, Pishvaian MJ, Holcombe RF, Marshall JL, Morse MA.

J Gastrointest Oncol. 2019 Aug;10(4):652-662. doi: 10.21037/jgo.2018.08.18.

2.

Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition.

Dhir T, Schultz CW, Jain A, Brown SZ, Haber A, Goetz A, Xi C, Su GH, Xu L, Posey J 3rd, Jiang W, Yeo CJ, Golan T, Pishvaian MJ, Brody JR.

Mol Cancer Res. 2019 Aug 5. doi: 10.1158/1541-7786.MCR-19-0589. [Epub ahead of print]

PMID:
31383722
3.

Multi-omic molecular comparison of primary versus metastatic pancreatic tumours.

Brar G, Blais EM, Joseph Bender R, Brody JR, Sohal D, Madhavan S, Picozzi VJ, Hendifar AE, Chung VM, Halverson D, Mikhail S, Matrisian LM, Rahib L, Petricoin E, Pishvaian MJ.

Br J Cancer. 2019 Jul;121(3):264-270. doi: 10.1038/s41416-019-0507-5. Epub 2019 Jul 11.

PMID:
31292535
4.

Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer.

Jain A, Agostini LC, McCarthy GA, Chand SN, Ramirez A, Nevler A, Cozzitorto J, Schultz CW, Lowder CY, Smith KM, Waddell ID, Raitses-Gurevich M, Stossel C, Gorman YG, Atias D, Yeo CJ, Winter JM, Olive KP, Golan T, Pishvaian MJ, Ogilvie D, James DI, Jordan AM, Brody JR.

Cancer Res. 2019 Sep 1;79(17):4491-4502. doi: 10.1158/0008-5472.CAN-18-3645. Epub 2019 Jul 4.

PMID:
31273064
5.

The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.

Parasido E, Avetian GS, Naeem A, Graham G, Pishvaian M, Glasgow E, Mudambi S, Lee Y, Ihemelandu C, Choudhry M, Peran I, Banerjee PP, Avantaggiati ML, Bryant K, Baldelli E, Pierobon M, Liotta L, Petricoin E, Fricke ST, Sebastian A, Cozzitorto J, Loots GG, Kumar D, Byers S, Londin E, DiFeo A, Narla G, Winter J, Brody JR, Rodriguez O, Albanese C.

Mol Cancer Res. 2019 Sep;17(9):1815-1827. doi: 10.1158/1541-7786.MCR-19-0191. Epub 2019 Jun 4.

PMID:
31164413
6.

A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Tesfaye AA, Wang H, Hartley ML, He AR, Weiner L, Gabelia N, Kapanadze L, Shezad M, Brody JR, Marshall JL, Pishvaian MJ.

J Pancreat Cancer. 2019 May 2;5(1):12-21. doi: 10.1089/pancan.2019.0003. eCollection 2019.

7.

Genetic Drivers of Pancreatic Cancer Are Identical Between the Primary Tumor and a Secondary Lesion in a Long-Term (>5 Years) Survivor After a Whipple Procedure.

Bauer TM, Dhir T, Strickland A, Thomsett H, Goetz AB, Cannaday S, Brody JR, Pishvaian MJ, Yeo CJ.

J Pancreat Cancer. 2018 Nov 1;4(1):81-87. doi: 10.1089/pancan.2018.0015. eCollection 2018. Review.

8.

Correction: Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.

Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL.

Cancer Res. 2019 Feb 15;79(4):874. doi: 10.1158/0008-5472.CAN-18-4086. No abstract available.

PMID:
30770369
9.

Sorafenib for Advanced and Refractory Desmoid Tumors.

Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK.

N Engl J Med. 2018 Dec 20;379(25):2417-2428. doi: 10.1056/NEJMoa1805052.

10.

Molecular Profiling of Pancreatic Cancer Patients-Response.

Pishvaian MJ, Petricoin E 3rd.

Clin Cancer Res. 2018 Dec 15;24(24):6612. doi: 10.1158/1078-0432.CCR-18-2645. No abstract available.

PMID:
30552237
11.

Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types.

Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen WJ, Baker TM, Marshall JL, Isaacs C.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00286. Epub 2018 Jul 23.

12.

Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative.

Pishvaian MJ, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S, Chung V, Picozzi VJ, Sohal D, Blais EM, Mason K, Lyons EE, Matrisian LM, Brody JR, Madhavan S, Petricoin EF 3rd.

Clin Cancer Res. 2018 Oct 15;24(20):5018-5027. doi: 10.1158/1078-0432.CCR-18-0531. Epub 2018 Jun 28.

PMID:
29954777
13.

A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.

Pishvaian MJ, Slack RS, Jiang W, He AR, Hwang JJ, Hankin A, Dorsch-Vogel K, Kukadiya D, Weiner LM, Marshall JL, Brody JR.

Cancer. 2018 Jun 1;124(11):2337-2346. doi: 10.1002/cncr.31309. Epub 2018 Mar 26.

14.

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.

Segal NH, He AR, Doi T, Levy R, Bhatia S, Pishvaian MJ, Cesari R, Chen Y, Davis CB, Huang B, Thall AD, Gopal AK.

Clin Cancer Res. 2018 Apr 15;24(8):1816-1823. doi: 10.1158/1078-0432.CCR-17-1922. Epub 2018 Mar 16.

15.

A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies.

Deeken JF, Wang H, Hartley M, Cheema AK, Smaglo B, Hwang JJ, He AR, Weiner LM, Marshall JL, Giaccone G, Liu S, Luecht J, Spiegel JY, Pishvaian MJ.

Cancer Chemother Pharmacol. 2018 Mar;81(3):587-596. doi: 10.1007/s00280-018-3533-8. Epub 2018 Feb 1.

PMID:
29392450
16.

A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative.

Pishvaian MJ, Joseph Bender R, Matrisian LM, Rahib L, Hendifar A, Hoos WA, Mikhail S, Chung V, Picozzi V, Heartwell C, Mason K, Varieur K, Aberra M, Madhavan S, Petricoin E 3rd, Brody JR.

Oncotarget. 2016 Nov 8;8(48):83446-83456. doi: 10.18632/oncotarget.13225. eCollection 2017 Oct 13.

17.

Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors.

Chand SN, Zarei M, Schiewer MJ, Kamath AR, Romeo C, Lal S, Cozzitorto JA, Nevler A, Scolaro L, Londin E, Jiang W, Meisner-Kober N, Pishvaian MJ, Knudsen KE, Yeo CJ, Pascal JM, Winter JM, Brody JR.

Cancer Res. 2017 Sep 15;77(18):5011-5025. doi: 10.1158/0008-5472.CAN-16-2704. Epub 2017 Jul 7.

18.

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.

Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, Carrigan M, Saraf S, Chen M, Soria JC.

J Clin Oncol. 2017 Aug 1;35(22):2535-2541. doi: 10.1200/JCO.2017.72.5952. Epub 2017 May 10.

PMID:
28489510
19.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.

Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J.

Ann Oncol. 2017 May 1;28(5):1036-1041. doi: 10.1093/annonc/mdx029.

20.

Academic Cancer Center Phase I Program Development.

Frankel AE, Flaherty KT, Weiner GJ, Chen R, Azad NS, Pishvaian MJ, Thompson JA, Taylor MH, Mahadevan D, Lockhart AC, Vaishampayan UN, Berlin JD, Smith DC, Sarantopoulos J, Riese M, Saleh MN, Ahn C, Frenkel EP.

Oncologist. 2017 Apr;22(4):369-374. doi: 10.1634/theoncologist.2016-0409. Epub 2017 Mar 17.

21.

Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.

Pishvaian MJ, Brody JR.

Oncology (Williston Park). 2017 Mar 15;31(3):159-66, 168. Review.

22.

BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.

Pishvaian MJ, Biankin AV, Bailey P, Chang DK, Laheru D, Wolfgang CL, Brody JR.

Br J Cancer. 2017 Apr 11;116(8):1021-1026. doi: 10.1038/bjc.2017.40. Epub 2017 Mar 14.

23.

Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.

Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL.

Cancer Res. 2017 May 1;77(9):2488-2499. doi: 10.1158/0008-5472.CAN-16-2653. Epub 2017 Mar 1. Erratum in: Cancer Res. 2019 Feb 15;79(4):874.

24.

Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer.

Lischalk JW, Burke A, Chew J, Elledge C, Gurka M, Marshall J, Pishvaian M, Collins S, Unger K.

J Gastrointest Cancer. 2018 Jun;49(2):116-123. doi: 10.1007/s12029-016-9909-2.

PMID:
28044263
25.

Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.

Rao S, Beckman RA, Riazi S, Yabar CS, Boca SM, Marshall JL, Pishvaian MJ, Brody JR, Madhavan S.

Oncotarget. 2017 Jun 6;8(23):37923-37934. doi: 10.18632/oncotarget.13544. Review.

26.

WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.

Lal S, Zarei M, Chand SN, Dylgjeri E, Mambelli-Lisboa NC, Pishvaian MJ, Yeo CJ, Winter JM, Brody JR.

Sci Rep. 2016 Sep 12;6:33323. doi: 10.1038/srep33323.

27.

Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.

Pishvaian M, Morse MA, McDevitt J, Norton JD, Ren S, Robbie GJ, Ryan PC, Soukharev S, Bao H, Denlinger CS.

Clin Colorectal Cancer. 2016 Dec;15(4):345-351. doi: 10.1016/j.clcc.2016.07.009. Epub 2016 Aug 4.

PMID:
27591895
28.

Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer.

Brody JR, Yabar CS, Zarei M, Bender J, Matrisian LM, Rahib L, Heartwell C, Mason K, Yeo CJ, Peiper SC, Jiang W, Varieur K, Madhavan S, Petricoin E 3rd, Fortuna D, Curtis M, Wang ZX, Pishvaian MJ, Winter JM.

Cancer Biol Ther. 2018 Apr 3;19(4):249-253. doi: 10.1080/15384047.2016.1210743. Epub 2018 Mar 6.

29.
30.

A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.

LaBonte MJ, Yang D, Zhang W, Wilson PM, Nagarwala YM, Koch KM, Briner C, Kaneko T, Rha SY, Gladkov O, Urba SG, Sakaeva D, Pishvaian MJ, Hsieh RK, Lee WP, Lenz HJ.

Mol Cancer Ther. 2016 Sep;15(9):2251-8. doi: 10.1158/1535-7163.MCT-15-0908. Epub 2016 Jun 20.

31.

Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer.

Tian X, Shivapurkar N, Wu Z, Hwang JJ, Pishvaian MJ, Weiner LM, Ley L, Zhou D, Zhi X, Wellstein A, Marshall JL, He AR.

Oncol Lett. 2016 Mar;11(3):1645-1650. Epub 2016 Jan 13.

32.

Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma.

Weinberg BA, Yabar CS, Brody JR, Pishvaian MJ.

Oncology (Williston Park). 2015 Nov;29(11):809-20, 886. Review.

33.

A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies.

Lubner SJ, Mullvain J, Perlman S, Pishvaian M, Mortimer J, Oliver K, Heideman J, Hall L, Weichert J, Liu G.

Cancer Invest. 2015;33(10):483-9. doi: 10.3109/07357907.2015.1081691. Epub 2015 Nov 4.

PMID:
26536061
34.

Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.

Wu Z, Gabrielson A, Hwang JJ, Pishvaian MJ, Weiner LM, Zhuang T, Ley L, Marshall JL, He AR.

Cancer Chemother Pharmacol. 2015 Dec;76(6):1309-14. doi: 10.1007/s00280-015-2855-z. Epub 2015 Oct 27.

PMID:
26507197
35.

Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.

Gabrielson A, Tesfaye AA, Marshall JL, Pishvaian MJ, Smaglo B, Jha R, Dorsch-Vogel K, Wang H, He AR.

Cancer Chemother Pharmacol. 2015 Nov;76(5):1073-9. doi: 10.1007/s00280-015-2852-2. Epub 2015 Oct 8.

36.

Retrievable inferior vena cava filters in patients with cancer are safe but are they beneficial?

Mikhail S, Hannan L, Pishvaian MJ, Kessler C.

Med Oncol. 2015 Jun;32(6):622. doi: 10.1007/s12032-015-0622-y. Epub 2015 Apr 29.

PMID:
25920612
37.

Cyclin-dependent kinase inhibitors and the treatment of gastrointestinal cancers.

Mikhail S, Albanese C, Pishvaian MJ.

Am J Pathol. 2015 May;185(5):1185-97. doi: 10.1016/j.ajpath.2015.01.008. Epub 2015 Mar 5. Review.

38.

A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.

Deeken JF, Wang H, Subramaniam D, He AR, Hwang J, Marshall JL, Urso CE, Wang Y, Ramos C, Steadman K, Pishvaian MJ.

Cancer. 2015 May 15;121(10):1645-53. doi: 10.1002/cncr.29224. Epub 2015 Jan 29.

39.

Upgrading gemcitabine with recycled kinase inhibitors.

Blanco FF, Pishvaian MJ, Brody JR.

Cell Cycle. 2014;13(18):2810-1. doi: 10.4161/15384101.2014.954211. No abstract available.

40.

Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.

Subramaniam D, He AR, Hwang J, Deeken J, Pishvaian M, Hartley ML, Marshall JL.

Curr Cancer Drug Targets. 2015;14(9):775-93. Review.

PMID:
25435079
41.

PARP inhibitors for chemoprevention--letter.

Chand SN, Blanco FF, Jimbo M, Tsangaris TN, Cristofanilli M, Yeo CJ, Winter JM, Pishvaian MJ, Brody JR.

Cancer Prev Res (Phila). 2014 Nov;7(11):1170-1. doi: 10.1158/1940-6207.CAPR-14-0220. No abstract available.

42.

Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy: a retrospective cohort study.

Weinberg BA, Wang H, Yang X, Wu CS, Pishvaian MJ, He AR, Marshall JL, Hwang JJ.

Gastrointest Cancer Res. 2014 May;7(3-4):91-7.

43.

Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma.

Gurka MK, Kim C, He AR, Charabaty A, Haddad N, Turocy J, Johnson L, Jackson P, Weiner LM, Marshall JL, Collins SP, Pishvaian MJ, Unger K.

Am J Clin Oncol. 2017 Apr;40(2):152-157. doi: 10.1097/COC.0000000000000118.

44.

Profile and potential of ixabepilone in the treatment of pancreatic cancer.

Smaglo BG, Pishvaian MJ.

Drug Des Devel Ther. 2014 Jul 14;8:923-30. doi: 10.2147/DDDT.S52964. eCollection 2014. Review.

45.

Human Pancreatic Cancer-Associated Stellate Cells Remain Activated after in vivo Chemoradiation.

Cabrera MC, Tilahun E, Nakles R, Diaz-Cruz ES, Charabaty A, Suy S, Jackson P, Ley L, Slack R, Jha R, Collins SP, Haddad N, Kallakury BV, Schroeder T, Pishvaian MJ, Furth PA.

Front Oncol. 2014 May 9;4:102. doi: 10.3389/fonc.2014.00102. eCollection 2014.

46.

A phase I study of oral ixabepilone in patients with advanced solid tumors.

Deeken JF, Marshall JL, Pishvaian MJ, Hwang J, Ahlers CM, Clemens PL, Parker SM, Iacono L, LoRusso PM.

Cancer Chemother Pharmacol. 2014 May;73(5):1071-8. doi: 10.1007/s00280-014-2443-7. Epub 2014 Mar 25.

PMID:
24663504
47.

Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine.

Harris M, Bhuvaneshwar K, Natarajan T, Sheahan L, Wang D, Tadesse MG, Shoulson I, Filice R, Steadman K, Pishvaian MJ, Madhavan S, Deeken J.

Pharmacogenet Genomics. 2014 Feb;24(2):81-93. doi: 10.1097/FPC.0000000000000015. Erratum in: Pharmacogenet Genomics. 2014 Jun;24(6):329.

48.

Targeting the BRCA1/2 tumor suppressors.

Rosen EM, Pishvaian MJ.

Curr Drug Targets. 2014 Jan;15(1):17-31.

PMID:
24387337
49.

Future of targeted agents in metastatic colorectal cancer.

Burotto M, Hartley ML, Marshall JL, Pishvaian MJ.

Colorectal Cancer. 2012 Oct;1(5). doi: 10.2217/crc.12.52.

50.

Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.

Gurka MK, Collins SP, Slack R, Tse G, Charabaty A, Ley L, Berzcel L, Lei S, Suy S, Haddad N, Jha R, Johnson CD, Jackson P, Marshall JL, Pishvaian MJ.

Radiat Oncol. 2013 Mar 1;8:44. doi: 10.1186/1748-717X-8-44.

Supplemental Content

Loading ...
Support Center